<!doctype html>
<meta charset="utf-8">
<title>S31 · Chat</title>
<style>
  body { font-family:-apple-system,system-ui,Segoe UI,Roboto,Helvetica,Arial,sans-serif; background:#fafafa; margin:24px; }
  .wrap { max-width: 900px; margin: 0 auto; }
  .hdr a { text-decoration:none; color:#2563eb; }
  .badge { display:inline-block; font-size:12px; font-weight:600; padding:4px 8px; border-radius:999px; }
  .pass { background:#ecfdf5; color:#065f46; }
  .fail { background:#fef2f2; color:#991b1b; }
  .score { color:#64748b; margin-left:8px; font-weight:500; }
  .topfindings { background:#fff; padding:12px 14px; border-radius:12px; box-shadow:0 1px 3px rgba(0,0,0,.08); margin:12px 0 20px; }
  .topfindings ul { margin:6px 0 0 18px; }
  .row { display:flex; gap:16px; margin:12px 0; }
  .bubble { padding:12px 14px; border-radius:14px; line-height:1.35; box-shadow:0 1px 3px rgba(0,0,0,.08); background:white; }
  .rep   { justify-content:flex-end; }
  .rep .bubble { background:#eef6ff; }
  .hcp .bubble { background:#fff; }
  .meta { color:#64748b; font-size:12px; margin-bottom:6px; }
  .ibox { margin-top:24px; border-top:1px dashed #e5e7eb; padding-top:14px; display:flex; gap:10px; }
  .ibox input { flex:1; padding:10px 12px; border:1px solid #e5e7eb; border-radius:10px; }
  .ibox button { padding:10px 14px; border:0; border-radius:10px; background:#111827; color:white; }
</style>
<div class="wrap">
  <div class="hdr">
    <div class="meta"><a href="../index.html">« Chat Index</a></div>
    <h2 style="margin:6px 0 10px 0;">S31</h2>
    <span class="badge pass">PASS</span><span class="score">Score: 92</span>
  </div>

  <div class="topfindings"><b>Top Findings</b><ul><li>on_label_compliance: Trodelvy (sacituzumab govitecan) is indicated for use in HR+/HER2- metastatic breast cancer after at least two prior therapies, including a CDK4/6 inhibitor and endocrine therapy.</li></ul></div>

  <div class="chat">
    <div class="row rep"><div class="bubble">
      <div class="meta">Sales Representative</div>Clinically, what are the on-label points I should know about Trodelvy in HR+/HER2- after prior CDK4/6?
    </div></div>

    <div class="row hcp"><div class="bubble">
      <div class="meta">Dr Tawel</div>Trodelvy (sacituzumab govitecan) is indicated for use in HR+/HER2- metastatic breast cancer after at least two prior therapies, including a CDK4/6 inhibitor and endocrine therapy. Its use is based on clinical evidence showing benefit in this setting. For more detailed information, I suggest reviewing the SmPC or EPAR. Could you send those documents by email for a closer look?
    </div></div>
  </div>

  <div class="ibox">
    <input placeholder="Message Dr Tawel" disabled value="">
    <button disabled>Send</button>
  </div>
</div>
